nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-C3E34723·Framework v5.10·Pipeline v0.4·Evaluated 06 Nov 2026·OECD: 3.1 Basic medicine·Basis: Full text·Type: Narrative review

Programming immunity in situ: A new frontier of in vivo cell engineering

Juliane Mietz et al.Juliane Mietz, Antonela Merlotti, Antonin de Fougerolles et al.·10.1126/sciimmunol.aed1027 ↗

Primary claim

In vivo immune cell engineering has entered clinical testing, but its development remains at an early stage.

Supported · small early-phase clinical cohorts establish feasibility rather than durable, reproducible clinical benefit
In brief

An integrated review maps delivery and safety choices for in vivo immune-cell engineering, but unreported source selection limits confidence in its evidence coverage.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Abstract

In vivo cell engineering enables the direct programming of immune cells inside patients. Instead of isolating, modifying, and reinfusing cells, therapeutic instructions are delivered directly to selected immune cells through lipid nanoparticles or viral vectors. This approach could facilitate rapid and scalable deployment of varied immune cell therapies across disease contexts. Early clinical studies in oncology and autoimmunity demonstrate increasing technical and clinical feasibility. The next challenge lies in enhancing precision to ensure that vectors reach the target cell type and tissue, deliver the appropriate payload, and produce desired transient or durable activity. Progress in targeting ligands, vector design, biodistribution control, and genome editing is beginning to address these barriers. Ensuring safety against immunogenicity, inflammatory toxicity, off-target editing, and uncontrolled persistence remains a central priority. By mastering these constraints, in vivo engineering could turn endogenous immune cells into therapeutic agents generated directly in the body, expanding cell therapy to diseases refractory to current modalities.

Key Claims

Primary finding · Supported

In vivo immune cell engineering has entered clinical testing, but its development remains at an early stage.

small early-phase clinical cohorts establish feasibility rather than durable, reproducible clinical benefit

Conclusions
Quote verified
Secondary · Supported

The next challenge lies in enhancing precision to ensure that vectors reach the target cell type and tissue, deliver the appropriate payload, and produce desired transient or durable activity.

recurring delivery and expression constraints across platforms support this qualitative assessment without systematic comparative weighting

Abstract
Quote verified
Secondary · Tentative

ADs [autoimmune diseases] providing the clearest clinical proof of concept for in vivo immune cell engineering.

a small SLE cohort with temporary responses does not establish comparative clinical superiority over oncology evidence

Disease applications, Autoimmune diseases
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Linked framework for therapy design choices

Figure 1 connects vector choice, cellular targets, targeting, expression duration, and safety rather than treating them as independent platform features. Table 1 makes the principal vector tradeoffs accessible.

↳ Figure 1; Table 1; Conclusions

#methodological rigour

Safety setbacks integrated into the argument

The review discusses early adverse events, autoimmune and HIV rebound, off-target delivery, and conflicting insertional-mutagenesis evidence. These findings inform its requirements for monitoring and control.

↳ Disease applications; Dynamic control to ensure safety; Insertional mutagenesis

#positioning

Limitations connected to clinical design decisions

Transient versus durable expression is tied to disease context, while the inability to quality-control engineered cells beforehand is linked to patient selection and outcome variability.

↳ Conclusions

Limitations

#methodological rigour

Literature selection and appraisal remain unreported

No search, inclusion, prioritization, or appraisal process is described despite extensive clinical and preclinical synthesis. Readers cannot determine how representative the selected evidence is.

↳ Article-wide source-selection reporting

#methodological rigour

Clinical evidence draws on uneven sources

Clinical statements rely partly on conference abstracts and news reports, and the VERVE-102 LDL reduction is cited to a company announcement. These sources are not consistently graded against peer-reviewed clinical evidence.

↳ Disease applications; References 9, 10, 98, 103

#application pathway

Clinical maturity limits immediate practical use

The clinical signals come from small early-phase studies, while most applications beyond T cells remain preclinical. The synthesis guides development choices but does not establish reproducible benefit or broad deployment readiness.

↳ Cellular targets; Disease applications; Conclusions

Does this match your read? Add your assessment ↓

Nabu Commentary

Figure 1 and Table 1 organize vector properties, cell targets, targeting strategies, and expression control into a useful design framework, although the contribution remains principally synthesis. The safety discussion incorporates adverse events, rebound, off-target delivery, and conflicting genotoxicity findings rather than relying only on favorable feasibility signals. The absence of a literature-selection or appraisal account constrains confidence in evidence coverage, while reliance on preliminary sources limits the weight of individual clinical examples. The conclusions appropriately retain early-stage qualifications and connect persistence and patient-cell fitness to clinical development.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.6±0.1

Contribution
3.4

The review integrates vectors, immune-cell targets, targeting layers, expression duration, and safety into linked design choices. Its advance is organizational synthesis rather than new evidence or resolution of a contested uncertainty.

Figure 1; Table 1; Conclusions
Methodological Rigour
3.5

The argument connects platform properties and clinical applications to delivery and safety constraints while engaging adverse outcomes and rebound. Unreported source selection and uneven source maturity limit confidence in the completeness and evidentiary weighting of the synthesis.

Article-wide source-selection reporting; Disease applications; Dynamic control to ensure safety; References 9, 10, 98, 103
Reporting
4.0

Descriptive headings, schematic figures, and the vector table make the design logic traceable, and the conclusions distinguish technical feasibility from established benefit. The comparative autoimmune proof-of-concept phrasing is less calibrated than its accompanying discussion.

Figures 1–3; Table 1; Disease applications, Autoimmune diseases; Conclusions
Positioning
4.0

The review positions in vivo engineering against ex vivo practice and engages conflicting safety evidence rather than presenting translation as settled. Limitations concerning persistence, patient-cell fitness, off-target delivery, and genotoxicity are connected to interpretation and development requirements.

Introduction; Dynamic control to ensure safety; Insertional mutagenesis; Conclusions

Lower confidence on Contribution — domain match limited.

Reliability

Caveats4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyNoted

The LDL cholesterol reduction reported for VERVE-102 is sourced to a company announcement rather than a peer-reviewed clinical report. Competing interests are disclosed.

Conflict of interest: declared

Reference IntegrityClean

187 references in manuscript 183 of 183 checkable references found in an index 4 are books, websites or datasets — counted, but not index-checkable

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 06 Nov 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Generic health relevance
Type of advanceSynthesis
Route to useSuggested
AdvanceConsolidates
CitationsNot available
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The strongest evidence synthesized is small early phase 1 clinical trials in cancer and lupus patients showing feasibility and early signs of efficacy, which is proof-of-concept rather than confirmatory validation.

From the paper
“in vivo engineering could turn endogenous immune cells into therapeutic agents generated directly in the body, expanding cell therapy to diseases refractory to current modalities”

The review names a real-world use of in vivo-engineered immune cells as therapeutic agents for refractory diseases, but does not specify who would apply its own synthesis.

Pathway

Pharmaceutical companies and clinical trial teams develop targeted mRNA-LNP and viral vector products that let clinicians generate CAR T and other engineered immune cell therapies inside patients.

Barrier

The field must still demonstrate selective cell targeting, safety against off-target delivery and toxicity, and reproducible durable benefit in larger confirmatory trials.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity

    Selvaraj, Livesey, Zhao, et al. · 2018 · Basic medicine

    Primary claim

    increased expression of GluA1 AMPA receptor (AMPAR) subunit occurs in MNs with C9ORF72 mutations that leads to increased Ca2+-permeable AMPAR expression and results in enhanced selective MN vulnerability to excitotoxicity.

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    Caveats
  2. Astrocytes regulate axonal mitochondrial transport deficits in C9ORF72 amyotrophic lateral sclerosis motor neurons

    Stavrou, Heffernan, Carter, et al. · 2026 · Basic medicine

    Primary claim

    human-induced pluripotent stem-cell-derived astrocytes carrying the C9ORF72 mutation disrupt mitochondrial axonal transport and mitochondrial function in cocultured motor neurons (MNs)

    Supported
    Evidence Score
    3.1±0.1
    Reliability
    Caveats
  3. Maternal Angiotensin Increases Placental Leptin in Early Gestation via an Alternative Renin-Angiotensin System Pathway: Suggesting a Link to Preeclampsia

    Olivia Nonn, Cornelius Fischer, Sabrina Geisberger, et al. · 2021 · Basic medicine

    Primary claim

    Ang IV decreases trophoblastic mitochondrial respiration and increases placental leptin via placental LNPEP.

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    Caveats

How the rubric works →